Literature DB >> 15830402

The effect of quetiapine on aggression and hostility in patients with schizophrenia.

Celso Arango1, Miguel Bernardo.   

Abstract

A post hoc analysis of data from three placebo-controlled, double-blind, randomized trials was carried out to determine the efficacy of quetiapine in aggression and hostility in patients with schizophrenia. Quetiapine treatment induced statistically significantly greater improvements in BPRS positive symptom cluster scores and three measures of hostility derived from the BPRS, compared with placebo, in patients symptomatic at baseline. A path analysis showed that the improvements in hostility were highly correlated with improvements in positive symptoms and there was no consistent relationship between sedation and hostility. Aggressive behaviour appears to be related to positive symptoms of schizophrenia. Quetiapine may be a suitable option for patients with schizophrenia and aggressive behaviour. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15830402     DOI: 10.1002/hup.686

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  5 in total

Review 1.  Pharmacological management of acute and persistent aggression in forensic psychiatry settings.

Authors:  Leslie Citrome; Jan Volavka
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

Authors:  Jan Volavka; Pál Czobor; Leslie Citrome; Richard A Van Dorn
Journal:  CNS Spectr       Date:  2013-11-28       Impact factor: 3.790

3.  Treating persistent adolescent aggression.

Authors:  John Peterson; Christopher Sheldon
Journal:  Curr Treat Options Neurol       Date:  2006-09       Impact factor: 3.972

4.  Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative study.

Authors:  Gabriella Gobbi; Stefano Comai; Guy Debonnel
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-07       Impact factor: 2.570

5.  New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine.

Authors:  Bernhard T Baune
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.